BioScrip (Nasdaq: BIOS) reported earnings on May 10. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), BioScrip beat expectations on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue shrank significantly and GAAP earnings per share dropped to a loss.

Margins contracted across the board.

Revenue details
 BioScrip logged revenue of $155.6 million. The two analysts polled by S&P Capital IQ hoped for revenue of $143.5 million on the same basis. GAAP reported sales were 19% higher than the prior-year quarter's $130.8 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at -$0.03. The two earnings estimates compiled by S&P Capital IQ anticipated -$0.01 per share. GAAP EPS were -$0.05 for Q1 compared to $0.05 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 34.4%, 480 basis points worse than the prior-year quarter. Operating margin was 2.9%, 210 basis points worse than the prior-year quarter. Net margin was -1.7%, 390 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $151.8 million. On the bottom line, the average EPS estimate is $0.02.

Next year's average estimate for revenue is $611.8 million. The average EPS estimate is $0.13.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 127 members out of 144 rating the stock outperform, and 17 members rating it underperform. Among 27 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give BioScrip a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on BioScrip is buy, with an average price target of $10.00.

If you're interested in health care stocks like BioScrip, you might want to expand your horizons to find maximum returns. Follow the money and meet a prime candidate for major returns in our new report, "Discover the Next Rule-Breaking Multibagger." Click here for instant access to this free report.